Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
423
Employees423
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
423
Employees423

CYTK Key Statistics

Market cap
6.25B
Market cap6.25B
Price-Earnings ratio
-11.02
Price-Earnings ratio-11.02
Dividend yield
Dividend yield
Average volume
1.56M
Average volume1.56M
High today
$61.00
High today$61.00
Low today
$58.64
Low today$58.64
Open price
$59.91
Open price$59.91
Volume
1.06M
Volume1.06M
52 Week high
$110.25
52 Week high$110.25
52 Week low
$25.98
52 Week low$25.98

CYTK News

TipRanks 2d
Cytokinetics hosts CLIMB Research Symposium - TipRanks.com - TipRanks

Cytokinetics announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium, May 17th, 2024 at the...

Yahoo Finance 3d
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology - Yahoo Finance

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company w...

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology - Yahoo Finance
TipRanks 3d
Cytokinetics Board Changes and Stockholder Meeting Outcomes - TipRanks.com - TipRanks

Cytokinetics (CYTK) has issued an update. Sandford D. Smith resigned from the Board of Directors of Cytokinetics just before the 2024 annual stockholders’ meet...

Analyst ratings

83%

of 18 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More CYTK News

Yahoo Finance 5d
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 - Yahoo Finance

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five present...

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 - Yahoo Finance
TipRanks 5d
Truist defends Cytokinetics, still sees 'best-in-class potential' - TipRanks.com - TipRanks

Truist is defending shares of Cytokinetics after the company presented Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic...

TipRanks 5d
Cytokinetics data confirm aficamten's competitive profile, says Morgan Stanley - TipRanks.com - TipRanks

Morgan Stanley says full results of the aficamten Phase 3 SEQUOIA-HCM study, presented in a late-breaking session at the European Society of Cardiology’s Heart...

TipRanks 6d
Cytokinetics price target lowered to $70 from $75 at BofA

BofA lowered the firm’s price target on Cytokinetics (CYTK) to $70 from $75 and keeps a Neutral rating on the shares after the company presented the full SEQUOI...

Investor's Business Daily 7d
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day

Cytokinetics (CYTK) said Monday its experimental drug "significantly" improved exercise capacity in heart-disease patients. The results could buoy Cytokinetics...

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
Yahoo Finance 7d
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the ... - Yahoo Finance

Cytokinetics, Incorporated Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints;...

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the ... - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.